<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34593637</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>40</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The nuclear ubiquitin ligase adaptor SPOP is a conserved regulator of C9orf72 dipeptide toxicity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2104664118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2104664118</ELocationID><Abstract><AbstractText>A hexanucleotide repeat expansion in the <i>C9orf72</i> gene is the most common cause of inherited amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Unconventional translation of the <i>C9orf72</i> repeat produces dipeptide repeat proteins (DPRs). Previously, we showed that the DPRs PR50 and GR50 are highly toxic when expressed in <i>Caenorhabditis elegans</i>, and this toxicity depends on nuclear localization of the DPR. In an unbiased genome-wide RNA interference (RNAi) screen for suppressors of PR50 toxicity, we identified 12 genes that consistently suppressed either the developmental arrest and/or paralysis phenotype evoked by PR50 expression. All of these genes have vertebrate homologs, and 7 of 12 contain predicted nuclear localization signals. One of these genes was <i>spop-1</i>, the <i>C. elegans</i> homolog of <i>SPOP</i>, a nuclear localized E3 ubiquitin ligase adaptor only found in metazoans. <i>SPOP</i> is also required for GR50 toxicity and functions in a genetic pathway that includes <i>cul-3</i>, which is the canonical E3 ligase partner for <i>SPOP</i> Genetic or pharmacological inhibition of <i>SPOP</i> in mammalian primary spinal cord motor neurons suppressed DPR toxicity without affecting DPR expression levels. Finally, we find that knockdown of bromodomain proteins in both <i>C. elegans</i> and mammalian neurons, which are known <i>SPOP</i> ubiquitination targets, suppresses the protective effect of <i>SPOP</i> inhibition. Together, these data suggest a model in which <i>SPOP</i> promotes the DPR-dependent ubiquitination and degradation of <i>BRD</i> proteins. We speculate the pharmacological manipulation of this pathway, which is currently underway for multiple cancer subtypes, could also represent an entry point for therapeutic intervention to treat <i>C9orf72</i> FTD/ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snoznik</LastName><ForeName>Carley</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medvedeva</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mojsilovic-Petrovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4187-7207</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudich</LastName><ForeName>Paige</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Cell Biology and Molecular Physiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oosten</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8688-9159</Identifier><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalb</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611; stl52@pitt.edu robert.kalb1@northwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamitina</LastName><ForeName>Todd</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7332-9075</Identifier><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224; stl52@pitt.edu robert.kalb1@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Cell Biology and Molecular Physiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS094921</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS096319</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD010440</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096746</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS087077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509761">SPOP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.-</RegistryNumber><NameOfSubstance UI="D008025">Ligases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008025" MajorTopicYN="N">Ligases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C. elegans</Keyword><Keyword MajorTopicYN="N">bromodomain proteins</Keyword><Keyword MajorTopicYN="N">genetic screen</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteasome</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34593637</ArticleId><ArticleId IdType="pmc">PMC8501779</ArticleId><ArticleId IdType="doi">10.1073/pnas.2104664118</ArticleId><ArticleId IdType="pii">2104664118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M., et al. ., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E., et al. ., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., et al. ., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study. Lancet Neurol. 11, 54&#x2013;65 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A. M., C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 14, 544&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S. C., Polymenidou M., Cleveland D. W., Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., et al. ., RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y. S., et al. ., Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 2, 70 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229740</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., et al. ., Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., et al. ., C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A., et al. ., Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., et al. ., The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B. D., et al. ., GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., et al. ., Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 24, 1136&#x2013;1142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., et al. ., In situ structure of neuronal C9orf72 Poly-GA aggregates reveals proteasome recruitment. Cell 172, 696&#x2013;705.e12 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., et al. ., The proline/arginine dipeptide from hexanucleotide repeat expanded C9ORF72 inhibits the proteasome. eNeuro 4, ENEURO.0249-16.2017 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282547</ArticleId><ArticleId IdType="pubmed">28197542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., et al. ., Evidence that C9ORF72 dipeptide repeat proteins associate with U2 snRNP to cause Mis-splicing in ALS/FTD patients. Cell Rep. 19, 2244&#x2013;2256 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="pubmed">28614712</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. Y., et al. ., C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 22, 851&#x2013;862 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., et al. ., Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol. Cell 65, 1044&#x2013;1055.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K. H., et al. ., C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell 167, 774&#x2013;788.e17 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer N. J., et al. ., CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat. Genet. 50, 603&#x2013;612 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudich P., et al. ., Nuclear localized C9orf72-associated arginine-containing dipeptides exhibit age-dependent toxicity in C. elegans. Hum. Mol. Genet. 26, 4916&#x2013;4928 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886095</ArticleId><ArticleId IdType="pubmed">29036691</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., et al. ., Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 6, 20877 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., et al. ., Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell 167, 789&#x2013;802.e12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki Y., et al. ., Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Mol. Neurodegener. 12, 6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237533</ArticleId><ArticleId IdType="pubmed">28088213</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M. A., et al. ., C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 26, 4093&#x2013;4094 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886132</ArticleId><ArticleId IdType="pubmed">28973528</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M. A., Konopka A., Soo K. Y., Ito D., Atkin J. D., The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 26, 2882&#x2013;2896 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A., Burleson M., SPOP and cancer: A systematic review. Am. J. Cancer Res. 10, 704&#x2013;726 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136909</ArticleId><ArticleId IdType="pubmed">32266086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N., Gitler A. D., Yeast screen for modifiers of C9orf72 poly(glycine-arginine) dipeptide repeat toxicity. FEMS Yeast Res. 18, foy024 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946852</ArticleId><ArticleId IdType="pubmed">29528392</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer S. E., et al. ., Multiple small RNA pathways regulate the silencing of repeated and foreign genes in C. elegans. Genes Dev. 27, 2678&#x2013;2695 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877757</ArticleId><ArticleId IdType="pubmed">24352423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski A. M., et al. ., Loss of RAD-23 protects against models of motor neuron disease by enhancing mutant protein clearance. J. Neurosci. 35, 14286&#x2013;14306 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683688</ArticleId><ArticleId IdType="pubmed">26490867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai J., et al. ., Inhibition of cytohesins protects against genetic models of motor neuron disease. J. Neurosci. 35, 9088&#x2013;9105 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469736</ArticleId><ArticleId IdType="pubmed">26085633</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., et al. ., SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25, 455&#x2013;468 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443692</ArticleId><ArticleId IdType="pubmed">24656772</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z. Q., et al. ., Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell 30, 474&#x2013;484 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27622336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., et al. ., Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilan O., et al. ., Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science 368, 387&#x2013;394 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610820</ArticleId><ArticleId IdType="pubmed">32193360</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai Y., et al. ., Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett. 418, 23&#x2013;26 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9414087</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzahn M. R., et al. ., Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles. EMBO J. 35, 1254&#x2013;1275 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910529</ArticleId><ArticleId IdType="pubmed">27220849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard J. J., et al. ., Cancer mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments. Mol. Cell 72, 19&#x2013;36.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179159</ArticleId><ArticleId IdType="pubmed">30244836</ArticleId></ArticleIdList></Reference><Reference><Citation>White M. R., et al. ., C9orf72 Poly(PR) dipeptide repeats disturb biomolecular phase separation and disrupt nucleolar function. Mol. Cell 74, 713&#x2013;728.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525025</ArticleId><ArticleId IdType="pubmed">30981631</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng C., et al. ., Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. U.S.A. 110, 6997&#x2013;7002 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637757</ArticleId><ArticleId IdType="pubmed">23559371</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbieri C. E., et al. ., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685&#x2013;689 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673022</ArticleId><ArticleId IdType="pubmed">22610119</ArticleId></ArticleIdList></Reference><Reference><Citation>Blattner M., et al. ., SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16, 14&#x2013;20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924544</ArticleId><ArticleId IdType="pubmed">24563616</ArticleId></ArticleIdList></Reference><Reference><Citation>Blattner M., et al. ., SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell 31, 436&#x2013;451 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5384998</ArticleId><ArticleId IdType="pubmed">28292441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai X., et al. ., Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med. 23, 1063&#x2013;1071 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5625299</ArticleId><ArticleId IdType="pubmed">28805820</ArticleId></ArticleIdList></Reference><Reference><Citation>Janouskova H., et al. ., Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat. Med. 23, 1046&#x2013;1054 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592092</ArticleId><ArticleId IdType="pubmed">28805821</ArticleId></ArticleIdList></Reference><Reference><Citation>Theurillat J. P., et al. ., Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346, 85&#x2013;89 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257137</ArticleId><ArticleId IdType="pubmed">25278611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., et al. ., SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. J. Exp. Clin. Cancer Res. 37, 145 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6042370</ArticleId><ArticleId IdType="pubmed">29996942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., et al. ., Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat. Med. 23, 1055&#x2013;1062 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5653288</ArticleId><ArticleId IdType="pubmed">28805822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisawa T., Filippakopoulos P., Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat. Rev. Mol. Cell Biol. 18, 246&#x2013;262 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28053347</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman A., et al. ., A chemical screen identifies compounds limiting the toxicity of C9ORF72 dipeptide repeats. Cell Chem. Biol. 26, 235&#x2013;243.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30527999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z., et al. ., Structure-activity relationship of SPOP inhibitors against kidney cancer. J. Med. Chem. 63, 4849&#x2013;4866 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32297747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohlfing A. K., Miteva Y., Moronetti L., He L., Lamitina T., The Caenorhabditis elegans mucin-like protein OSM-8 negatively regulates osmosensitive physiology via the transmembrane protein PTR-23. PLoS Genet. 7, e1001267 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017116</ArticleId><ArticleId IdType="pubmed">21253570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamitina T., Huang C. G., Strange K., Genome-wide RNAi screening identifies protein damage as a regulator of osmoprotective gene expression. Proc. Natl. Acad. Sci. U.S.A. 103, 12173&#x2013;12178 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567714</ArticleId><ArticleId IdType="pubmed">16880390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanta K. S., Mello C. C., Melting dsDNA donor molecules greatly improves precision genome editing in Caenorhabditis elegans. Genetics 216, 643&#x2013;650 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648581</ArticleId><ArticleId IdType="pubmed">32963112</ArticleId></ArticleIdList></Reference><Reference><Citation>David F. P., Rougemont J., Deplancke B., GETPrime 2.0: Gene- and transcript-specific qPCR primers for 13 species including polymorphisms. Nucleic Acids Res. 45 (D1), D56&#x2013;D60 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210624</ArticleId><ArticleId IdType="pubmed">28053161</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudich P., Snoznik C., Puleo N., Lamitina T., Measuring RAN peptide toxicity in C. elegans. J. Vis. Exp. 158, 10.3791/61024 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/61024</ArticleId><ArticleId IdType="pmc">PMC8265314</ArticleId><ArticleId IdType="pubmed">32420986</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., et al. ., Poly(ADP-Ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol. Cell 71, 703&#x2013;717.e9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P., Uner O. E., Nayak S., Grant G. R., Kalb R. G., SAP97 regulates behavior and expression of schizophrenia risk enriched gene sets in mouse hippocampus. PLoS One 13, e0200477 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040763</ArticleId><ArticleId IdType="pubmed">29995933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojsilovic-Petrovic J., et al. ., Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci. 26, 9250&#x2013;9263 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674510</ArticleId><ArticleId IdType="pubmed">16957081</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S. K., et al. ., OASIS 2: Online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research. Oncotarget 7, 56147&#x2013;56152 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302902</ArticleId><ArticleId IdType="pubmed">27528229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J. S., et al. ., OASIS: Online application for the survival analysis of lifespan assays performed in aging research. PLoS One 6, e23525 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156233</ArticleId><ArticleId IdType="pubmed">21858155</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata Y., Takeshita H., Sasakawa N., Sawa H., Double bromodomain protein BET-1 and MYST HATs establish and maintain stable cell fates in C. elegans. Development 137, 1045&#x2013;1053 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20181741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>